Tabrecta: adverse event reports filed with FDA

1,918

reports as suspect product

0% of all reports · about 281 a year

70

reports, 12 months to June 2026

113 in the 12 months before

53.8%

marked serious by the reporter

70.8% across the class

22.5%

record death among outcomes, as reported

432 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Tabrecta reports recording the termmedian drug in kinase inhibitor

1. Deaththe patient died; cause not stated by this term17.7%340
2. Peripheral swellingswelling of the arms or legs14.7%282
3. Fatiguetiredness12.6%242
4. Nauseafeeling sick11.1%213
5. Oedema peripheralswelling of the legs, ankles or hands9.9%189
6. Dyspnoeashortness of breath6.3%121
7. Oedemaswelling from fluid5.7%110
8. Astheniaweakness or lack of energy5.3%101
9. Malignant neoplasm progression5.1%97
10. Joint swellinga swollen joint4.7%90
11. Decreased appetitereduced appetite4.4%84
12. Dysphagiadifficulty swallowing4.1%78
13. Product dose omission issuea dose was missed4%76
14. Vomitingbeing sick3.7%71
15. Dizzinesslight-headedness or unsteadiness3.6%69
16. Swellingswelling3%58
17. Coughcough2.9%56
18. Blood creatinine increasedraised creatinine, a kidney test2.8%53
19. Fluid retentionthe body holding extra fluid2.7%52
20. Pleural effusionfluid around the lung2.5%48
21. Non-small cell lung cancer2.3%45
22. Diarrhoealoose or frequent stools2.3%44
23. Drug ineffectivethe medicine did not work as expected2.3%44
24. Hypoacusisreduced hearing2.3%44
25. Back painback pain2.1%41
26. Painpain, site not specified2.1%40
27. Rashskin rash2.1%40
28. Weight increasedweight gain2%39
29. Lung neoplasm malignantlung cancer2%38
30. Thrombosis1.9%36

Top 30 of 289 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 100 drugs in the kinase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 849,161 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 86.9% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 1,918 reports.

Drugs most often listed in the same reports

Other products listed in reports where Tabrecta is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the kinase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Tabrecta as a suspect or interacting product; reports listing it only as a concomitant medication (24) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.